Dermapharm Approves EUR 0.88 Dividend as Growth Continues

Dermapharm Holding SE held its Annual General Meeting, concluding with a decision to distribute a EUR 0.88 dividend per share. Shareholders widely approved the Board's proposals, confirming support for the company's strategies. The meeting ratified the actions of the Board of Management and the Supervisory Board, securing overwhelming votes.

The company's strategic focus includes integrating the Mucos Group and expanding its European healthcare operations. Dermapharm aims to maintain its trajectory of profitable growth through brand innovation and an extensive European supply network. The company eyes substantial revenue targets and adjusted EBITDA growth for 2026.

Dermapharm has displayed robust performance, marked by improved profitability, cash flow, and reduced debt. This positions the company well for strategic development and sustainable value creation. Leadership remains optimistic about achieving targets through a mix of organic and inorganic growth.